Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

Metabolic Dysfunctions

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (1) Amino Acid Derivatives (1) Apoptosis (2) Autophagy (2) Bacterial (1) Btk (1) Cyclophilin (1) Endogenous Metabolite (2) ERK (2) FABP (2) FAP (1) FXR (3) GPR119 (1) GSK-3 (2) HIF/HIF Prolyl-Hydroxylase (1) Influenza Virus (2) Interleukin Related (1) IPK Superfamily (1) Lactate Dehydrogenase (1) LDLR (1) Mitochondrial Metabolism (1) Mitophagy (1) MMP (2) PI3K (1) PPAR (2) Reactive Oxygen Species (1) Thyroid Hormone Receptor (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Endocrinology (1) Infection (5) Inflammation/Immunology (9) Metabolic Disease (22) Neurological Disease (6)

By Targets:

17β-HSD (1)

Amino Acid Derivatives (1)

Apoptosis (2)

Autophagy (2)

Bacterial (1)

Btk (1)

Cyclophilin (1)

Endogenous Metabolite (2)

ERK (2)

FABP (2)

FAP (1)

FXR (3)

GPR119 (1)

GSK-3 (2)

HIF/HIF Prolyl-Hydroxylase (1)

Influenza Virus (2)

Interleukin Related (1)

IPK Superfamily (1)

Lactate Dehydrogenase (1)

LDLR (1)

Mitochondrial Metabolism (1)

Mitophagy (1)

MMP (2)

PI3K (1)

PPAR (2)

Reactive Oxygen Species (1)

Thyroid Hormone Receptor (2)

By Research Areas:

Cancer (6)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (9)

Metabolic Disease (22)

Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-59291

Levacetylleucine N-Acetyl-L-leucine	Amino Acid Derivatives	Neurological Disease Metabolic Disease Inflammation/Immunology
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .

HY-N0035

Arctigenin Maximum Cited Publications 8 Publications Verification (-)-Arctigenin	MMP Influenza Virus Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

HY-156681A

(S)-STX-478	PI3K	Cancer
(S)-STX-478 is the S-enantiomer of STX-478. STX-478 is a selective inhibitor of PI3Kα mutants, preventing metabolic dysfunction and demonstrating antitumor activity in xenograft mouse models with PI3Kα mutant tumors .

HY-163032

FABP4-IN-3	FABP	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 K_i = 25 ± 3 ^a nM, FABP3 K_i = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .

HY-160168

BTK-IN-31	Btk	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .

HY-161279

Antibiofilm agent-5	Bacterial Lactate Dehydrogenase Reactive Oxygen Species	Infection
Antibiofilm agent-5 (compound 6c) is a multitargeting antibacterial agent with potent antibiofilm activity. Antibiofilm agent-5 could induce metabolic dysfunction by deactivating lactate dehydrogenase and promote the accumulation of reactive oxygen species to decrease the reduced glutathione and ultimately cause oxidative damage in bacteria. Antibiofilm agent-5 can be used for the research of refractory biofilm-intensified bacterial infections .

HY-172317

AZD2389	FAP	Metabolic Disease
AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis .

HY-173265

CypB-IN-1	Cyclophilin	Metabolic Disease Inflammation/Immunology
CypB-IN-1 (Compound 11) is an inhibitor of cyclophilin B (cyclophilin B) with a K_d value of 12 nM. CypB-IN-1 can be applied to the research field of metabolic dysfunction-associated steatohepatitis (MASH) and the liver fibrosis diseases resulting from it .

HY-159881

SHS206	Mitophagy	Metabolic Disease
SHS206 (compound 6n) is an orally active mitochondrial uncoupler that reduces hepatic triglyceride levels. SHS206 exhibits in vivo efficacy in the GAN mouse model and shows inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH) .

HY-162122

PPARα/γ agonist 3	PPAR	Inflammation/Immunology
PPARα/γ agonist 3 (Compound 4) is a dual agonist of PPARα/γ. PPARα/γ agonist 3 has anti-inflammatory activity, significantly reducing inflammatory markers such as IL-6 and MCP-1 on THP-1 macrophages through NF-κB activation. PPARα/γ agonist 3 can be used in the study of metabolic syndrome and metabolic dysfunction-related fatty liver disease (MAFLD) .

HY-N8423

α-Amyrin 1 Publications Verification	ERK GSK-3	Neurological Disease Metabolic Disease
α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .

HY-168046

ALG-055009	Thyroid Hormone Receptor	Metabolic Disease
ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC₅₀ value of 0.063 μM. In rats on a high-fat diet, ALG-055009 can lower total cholesterol levels. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .

HY-168629

FXR agonist 9	FXR	Metabolic Disease
FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC₅₀ of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl₄(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .

HY-172122

FXR/HSD17B13 modulator 1	FXR 17β-HSD	Metabolic Disease
FXR/HSD17B13 modulator 1 (compound 6) is a potent modulator of FXR/HSD17B13. FXR/HSD17B13 modulator 1 plays an important roel in metabolic dysfunction-associated steatohepatitis (MASH) research .

HY-N0035R

Arctigenin (Standard)	MMP Influenza Virus Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

HY-170369

SHO1122147	Mitochondrial Metabolism	Metabolic Disease
SHO1122147 (Compound 7m) affects the mitochondrial electron transport chain, exhibits mitochondrial uncoupling activity (EC₅₀=3.6 μM), and increases the oxygen consumption rate (OCR=69%) and promotes cellular respiration. SHO1122147 is orally active, and can be used in reaearch of obesity and metabolic dysfunction-associated steatohepatitis (MASH) .

HY-122706A

IP6K2-IN-2	IPK Superfamily	Metabolic Disease
IP6K2-IN-2 (Compound 6) is an IP6K2 inhibitor, with IC₅₀ values of 0.58 μM (IP6K2), 0.86 μM (IP6K1) and 3.08 μM (IP6K3). IP6K2-IN-2 can be used in research of obesity .

HY-125863B

Glucose 6-phosphate dehydrogenase (yeast, recombinant) G6PD (yeast, recombinant)	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .

HY-168713

LZ-007	FXR	Metabolic Disease
LZ-007 is an agonist for farnesoid X receptor (FXR) with an EC₅₀ of 51 nM measuring by TR-FRET assay, or an EC₅₀ of 76 nM in HepG2 cell. LZ-007 exhibits good pharmacokinetic characheristics in SD rats. LZ-007 ameliorates western diet and CCl4 (HY-Y0298)-induced mice metabolic dysfunction-associated steatohepatitis

HY-137899

Dephospho-CoA 1 Publications Verification	Endogenous Metabolite	Metabolic Disease Cancer
Dephospho-CoA is a key intermediate in the biosynthesis of coenzyme A (CoA), which is catalyzed by GTP-dependent dephospho-CoA kinase (DPCK) to generate CoA. Dephospho-CoA completes the final synthesis step of CoA through phosphorylation reaction and participates in energy metabolism and cell signaling. Dephospho-CoA can be used in research including cancer (such as regulating cell proliferation) and metabolic diseases (such as mitochondrial dysfunction) .

HY-171454

DA-1241	GPR119	Metabolic Disease Inflammation/Immunology
DA-1241 is a GPR119 agonist. DA-1241 reduces macrophage differentiation through downregulation of NFκB signaling by activating GPR119. DA-1241, alone and in combination with a DPP4 inhibitor, reduces liver inflammation and restores inflammation-related liver gene expression. DA-1241 can be used for the research of metabolic dysfunction-associated steatohepatitis (MASH) .

HY-N8423R

α-Amyrin (Standard)	ERK GSK-3	Neurological Disease Metabolic Disease
α-Amyrin (Standard) is the analytical standard of α-Amyrin. This product is intended for research and analytical applications. α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .

HY-159120

ZG-2291	HIF/HIF Prolyl-Hydroxylase	Metabolic Disease
ZG-2291 is a selective inhibitor targeting FIH (Factor Inhibiting HIF) with oral activity. By binding to FIH, ZG-2291 promotes a conformational flip of a catalytically important tyrosine, enabling selective inhibition of FIH without affecting other 2OG oxygenases in the JmjC subfamily. ZG-2291k enhances thermogenesis in ob/ob mice and improves obesity-related symptoms and metabolic dysfunctions. ZG-2291 holds promise for research in the field of obesity-related diseases .

HY-172883

ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-172661

Kylo-0603	Thyroid Hormone Receptor Interleukin Related LDLR	Infection Metabolic Disease
KYLO-0603 is an orally active, selective THR-β agonist (EC₅₀: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .

Cat. No.	Product Name

HY-L217

Mouse Metabolite Compound Library	334 compounds
Metabolic abnormalities lead to dysfunction of metabolic pathways and the accumulation or lack of metabolites, which are recognized hallmarks of the disease. The metabolite signature is closely related to the disease phenotype and is very useful for predicting the diagnosis and prognosis of the disease as well as monitoring treatment. Metabolites can be used as disease markers for diagnostic therapy. As the classic model of disease experiment in vivo, mice metabolites also play a role in disease diagnosis and mechanism research. MCE provides 334 mouse metabolites that can be used in disease research.

Mouse Metabolite Compound Library

334 compounds

Metabolic abnormalities lead to dysfunction of metabolic pathways and the accumulation or lack of metabolites, which are recognized hallmarks of the disease. The metabolite signature is closely related to the disease phenotype and is very useful for predicting the diagnosis and prognosis of the disease as well as monitoring treatment. Metabolites can be used as disease markers for diagnostic therapy. As the classic model of disease experiment in vivo, mice metabolites also play a role in disease diagnosis and mechanism research.

MCE provides 334 mouse metabolites that can be used in disease research.

HY-L064

Glutamine Metabolism Compound Library	1,247 compounds
Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH. Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment. MCE owns a unique collection of 1,247 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Glutamine Metabolism Compound Library

1,247 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,247 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Levacetylleucine N-Acetyl-L-leucine	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Amino Acid Derivatives
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .

Arctigenin Maximum Cited Publications 8 Publications Verification (-)-Arctigenin	Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Lignans Metabolic Disease Plants Compositae Caesalpinia magnifoliolata Metc. Endogenous metabolite Infection Human Gut Microbiota Metabolites Phenylpropanoids Inflammation/Immunology Disease Research Fields Cancer	MMP Influenza Virus Autophagy Apoptosis
Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

α-Amyrin 1 Publications Verification	Triterpenes Structural Classification other families Terpenoids Plants	ERK GSK-3
α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .

Dephospho-CoA 1 Publications Verification	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Dephospho-CoA is a key intermediate in the biosynthesis of coenzyme A (CoA), which is catalyzed by GTP-dependent dephospho-CoA kinase (DPCK) to generate CoA. Dephospho-CoA completes the final synthesis step of CoA through phosphorylation reaction and participates in energy metabolism and cell signaling. Dephospho-CoA can be used in research including cancer (such as regulating cell proliferation) and metabolic diseases (such as mitochondrial dysfunction) .

Arctigenin (Standard)	Structural Classification Human Gut Microbiota Metabolites Source classification Lignans Phenylpropanoids Plants Compositae Caesalpinia magnifoliolata Metc. Endogenous metabolite	MMP Influenza Virus Autophagy Apoptosis
Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .

α-Amyrin (Standard)	Triterpenes Structural Classification other families Terpenoids Plants	ERK GSK-3
α-Amyrin (Standard) is the analytical standard of α-Amyrin. This product is intended for research and analytical applications. α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks